Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Rating Lowered by TheStreet

Opiant Pharmaceuticals (NASDAQ:OPNTGet Rating) was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating in a report issued on Monday, TheStreetRatingsTable reports.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Opiant Pharmaceuticals in a research report on Wednesday, March 16th.

Opiant Pharmaceuticals stock opened at $21.99 on Monday. The company has a market cap of $111.49 million, a price-to-earnings ratio of 68.72 and a beta of 0.61. Opiant Pharmaceuticals has a 52-week low of $10.50 and a 52-week high of $37.71. The firm’s fifty day moving average is $24.71 and its 200 day moving average is $26.80. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.34.

Opiant Pharmaceuticals (NASDAQ:OPNTGet Rating) last announced its earnings results on Tuesday, March 15th. The technology company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.12. Opiant Pharmaceuticals had a return on equity of 7.69% and a net margin of 6.40%. During the same quarter last year, the firm earned ($0.16) earnings per share. On average, equities research analysts anticipate that Opiant Pharmaceuticals will post -4.42 earnings per share for the current fiscal year.

In other news, CEO Roger Crystal sold 1,995 shares of the stock in a transaction that occurred on Thursday, January 27th. The shares were sold at an average price of $26.15, for a total value of $52,169.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Phil Skolnick sold 1,518 shares of the stock in a transaction that occurred on Thursday, January 27th. The shares were sold at an average price of $26.19, for a total transaction of $39,756.42. The disclosure for this sale can be found here. Corporate insiders own 28.56% of the company’s stock.

Several large investors have recently bought and sold shares of OPNT. Dorsey Wright & Associates acquired a new stake in shares of Opiant Pharmaceuticals in the 4th quarter valued at $72,000. Morgan Stanley raised its stake in Opiant Pharmaceuticals by 11.8% during the 1st quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock worth $101,000 after acquiring an additional 1,000 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Opiant Pharmaceuticals during the 4th quarter worth $108,000. Advisor Group Holdings Inc. raised its stake in Opiant Pharmaceuticals by 102.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 6,325 shares of the technology company’s stock worth $163,000 after acquiring an additional 3,200 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Opiant Pharmaceuticals during the 4th quarter worth $216,000. 26.48% of the stock is owned by hedge funds and other institutional investors.

Opiant Pharmaceuticals Company Profile (Get Rating)

Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.

Read More

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.